文献速递浆细胞疾病造血干细胞移植与细胞治疗

美法仑预处理方案及CD34+细胞剂量与安排对AL型淀粉样变性移植后结局的影响

The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis.
PubMed 文献 · Am J Hematol · 2025-04-11

该研究纳入2003至2020年间9个中心接受自体干细胞移植的1704例AL型淀粉样变性患者,分析美法仑预处理剂量、天数、休息日及输注CD34+细胞剂量对移植结局的影响。结果显示,1天美法仑预处理、省略休息日及输注CD34+细胞≥4.5×10^6/kg与更好的血液学缓解和总生存相关,作者据此推荐上述方案用于AL型淀粉样变性的自体干细胞移植。

要点

  • 输注CD34+细胞≥4.5×10^6/kg与中性粒细胞和血小板植入时间更短相关。
  • 全剂量美法仑、1天预处理及省略休息日为移植后深度血液学缓解的独立预测因素。
  • 全剂量美法仑、无休息日及CD34+细胞≥4.5×10^6/kg为更优总生存的独立预测因素。

核心结论

  • 作者推荐AL型淀粉样变性自体干细胞移植采用1天美法仑预处理并输注CD34+细胞≥4.5×10^6/kg。
  • 全剂量美法仑、1天预处理及省略休息日与移植后更高深度血液学缓解独立相关。

研究设计与样本

  • 多中心研究,纳入2003至2020年间9个中心接受自体干细胞移植的AL型淀粉样变性患者1704例。
  • 收集美法仑预处理剂量、预处理天数、预处理与干细胞输注间是否设休息日及输注CD34+细胞剂量数据。

主要发现

  • 63.7%的患者接受全剂量美法仑(≥180 mg/m2),80.4%的患者美法仑分2天预处理。
  • 52.5%的患者在预处理方案与干细胞输注之间设有休息日(第-1天),输注CD34+细胞中位数为4.7×10^6/kg。
  • 输注CD34+细胞≥4.5×10^6/kg与中性粒细胞和血小板植入时间更短相关。
  • 中位随访8.6年,38%的患者死亡;全剂量美法仑、无休息日及输注CD34+细胞≥4.5×10^6/kg为更优总生存的独立预测因素。
  • 第100天移植相关死亡率更高的独立预测因素包括体能状态较差、NT-proBNP/BNP≥1800/400 pg/mL、血清白蛋白<2.5 g/dL、CD34+细胞<4.5×10^6/kg及无休息日。

关键数值与推荐

  • 全剂量美法仑定义为≥180 mg/m2,63.7%的患者接受该剂量。
  • 输注CD34+细胞阈值≥4.5×10^6/kg与植入时间更短相关,中位输注量为4.7×10^6/kg。
  • 第100天移植相关死亡率更高的独立预测因素包括NT-proBNP/BNP≥1800/400 pg/mL、血清白蛋白<2.5 g/dL及CD34+细胞<4.5×10^6/kg。

临床怎么用

  • 作者推荐AL型淀粉样变性自体干细胞移植采用1天美法仑预处理并输注CD34+细胞≥4.5×10^6/kg。
  • 全剂量美法仑、1天预处理及省略休息日与移植后更高深度血液学缓解独立相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal conditioning schedule and CD34+ cell dose for autologous stem cell transplantation (ASCT) for AL amyloidosis is unknown. Patients (n = 1704) who underwent ASCT for AL amyloidosis between 2003 and 2020 in 9 centers were included. Data on melphalan conditioning dose, number of conditioning days, whether a rest day between conditioning and stem cell infusion was given or not, and infused CD34+ cell dose were collected. Full-dose melphalan (≥ 180 mg/m2) was administered in 63.7% of the patients, and 80.4% had melphalan split into 2-day conditioning. A rest day (day -1) between the conditioning regimen and stem cell infusion was provided in 52.5% of patients. The median infused CD34+ cell count was 4.7 × 106/kg. An infused CD34+ cell count ≥ 4.5 × 106/kg was associated with a shorter time to neutrophil and platelet engraftment. In a nominal regression analysis, full-dose melphalan, 1-day melphalan conditioning, and omitting a rest day between conditioning and stem cell infusion were independent predictors of post-ASCT higher deep hematological response. The median follow-up was 8.6 years, and 38% of patients died. Independent predictors of superior overall survival in multivariate Cox regression analysis included full-dose melphalan, having no rest day, and infused CD34+ cells ≥ 4.5 × 106/kg. Independent predictors of higher day-100 transplant-related mortality (TRM) in nominal logistic regression analysis included poorer performance status, NT-proBNP/BNP ≥ 1800/400 pg/mL, serum albumin < 2.5 g/dL, CD34+ cells < 4.5 × 106/kg, and not having a rest day. In conclusion, 1 day of melphalan conditioning and administration of CD34+ cells ≥ 4.5 × 106/kg are recommended for ASCT in AL amyloidosis.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Muchtar E, Sanchorawala V, Hassan H, et al. The Impact of Melphalan Conditioning and CD34 + Cell Dose and Schedule on Post-Transplant Outcomes in AL Amyloidosis. Am J Hematol. 2025. PMID: 40214172. doi:10.1002/ajh.27685

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。